ArticleInfection & chemotherapy2024

Response to A Korean Post-Marketing Study of Abacavir/Dolutegravir/Lamivudine in Patients with HIV-1.

Sudip Bhattacharya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.